{
    "nctId": "NCT02796755",
    "briefTitle": "Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation",
    "officialTitle": "Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation",
    "overallStatus": "COMPLETED",
    "conditions": "Inflammation, Fatigue",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Central Nervous System (CNS) Glutamate Measured by Magnetic Resonance Spectroscopy (MRS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Must have completed surgery for Stage I-III breast cancer (lumpectomy or mastectomy) with or without neoadjuvant or adjuvant chemotherapy and with or without radiation.\n* Must be 1-5 years post-treatment for breast cancer\n* Must have a plasma c-reactive protein (CRP) level of \\>3mg/L\n* Must have a score of \u22654 (out of 10 points, 0 being no fatigue and 10 being severe, incapacitating fatigue) on a Single Item Screening Scale for Fatigue\n\nExclusion Criteria:\n\n* Presence of a medical condition that might represent a risk for riluzole treatment, including history of allergic reaction to riluzole and evidence of liver disease\n* Presence of a medical condition that might potentially confound the relationship among CNS glutamate, inflammation and behavior/cognition, including autoimmune or inflammatory disorders, chronic infectious diseases (e.g. HIV, hepatitis B or C), pregnancy, neurologic disorders (including a history of serious head trauma or seizures), liver disease (as manifested as an elevation in liver transaminases) and uncontrolled cardiovascular, metabolic, pulmonary or renal disease (as determined by medical history and laboratory testing)\n* Current or past history of schizophrenia\n* Individuals with bipolar disorder who have experienced a manic episode within 6 months of study entry, or at the discretion of the study doctor\n* Individuals receiving antidepressants, mood stabilizers, antipsychotic medications or benzodiazepines or drugs known to affect the immune system (e.g. glucocorticoids, methotrexate), or at the discretion of the study doctor\n* Individuals exhibiting signs of infection at the screening visit will be rescheduled to screen when symptoms have resolved",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}